GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Merck KGaA and Lonza Separately Acquire Indian Bioscience Companies

  • Merck KGaA’s Indian subsidiary, Merck Specialties Private, acquired Bangalore Genei Private (BGIP; India) from the Sanmar Group. Lonza separately announced taking over the preclinical cell and molecular biology assets of Bangalore-based Simbiosys Biowares India, a subsidiary of Texas-based cell biology services company Simbiosys Biowares.

    Bangalore Genei specializes in the development, production, and sales of products for proteomic and genomic research. The company generated total revenues of about €3 million in fiscal year 2008. Christina Shassere, global head of Merck’s bioscience business, says that BGIP’s portfolio is tailored to the requirements of the Indian market. “BGIP’s leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base”.

    Simbiosys Biowares India offers preclinical services for drug discovery (including lead validation and lead development) and molecular biology (DNA amplification, cloning, DNA/RNA isolation, synthetic gene construction, and quantitative PCR) along with process development services for small molecules, proteins, and mAbs.

    Anja Fiedler, head of Lonza Biosciences, maintains that the acquisition of the company’s cell and molecular biology assets in India fits in with Lonza’s strategy to further develop its life science platform and expand its global cell biology portfolio.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?